西班牙全国队列:系统性自身免疫病对母胎及新生儿结局的影响
基于西班牙2016-2022年全国住院数据库,分析1 973 249例妊娠住院中5 727例合并自身免疫病者,发现不同疾病具有特异的母胎风险模式,以SLE、APS(尤其继发性)和MCTD风险最高,Sarcoidosis无独立关联。
要点
- SLE、APS(尤其继发性)和MCTD先兆子痫及严重特征风险显著升高。
- Behçet病主要增加母体血栓风险(OR 9.31)。
- SSc增加母体及胎儿/新生儿复合发病风险,Sarcoidosis无独立关联。
核心结论
- 自身免疫病妊娠呈现疾病特异的子痫前期、母体及胎儿/新生儿风险模式,SLE、APS(尤其继发性)和MCTD风险最持续升高。
研究设计与样本
- 分析西班牙全国住院数据库(SNHDD)2016-2022年妊娠相关住院,暴露为SLE、原发性干燥综合征、MCTD、SSc、Sarcoidosis、Behçet病及APS(原发/继发),比较母胎结局。
主要发现
- 共1 973 249例妊娠住院,其中5 727例涉及自身免疫病。
- SLE:PE OR 1.78,PESC 2.17,复合母体1.35,胎儿/新生儿1.16。
- 原发性APS:PE 1.50,PESC 1.88,母体1.66,胎儿/新生儿1.10;继发性APS:PE 2.61,PESC 3.47,母体1.94。
- MCTD:PE 4.57,PESC 7.24;SSc:复合母体1.62,胎儿/新生儿1.69。
- Behçet病主要增加母体血栓(9.31);SjS增加剖宫产及部分胎儿结局;Sarcoidosis无独立关联。
关键数值与推荐
- 结局定义:PE、PESC、复合母体 morbidity(剖宫产、产后出血、血栓、卒中、ICU入住)及复合胎儿/新生儿 morbidity-mortality(胎儿窘迫、FGR、早产、胎盘早剥、死产、新生儿死亡)。
临床怎么用
- 上述比较性估计可支持风险分层、指南一致的照护,并用于咨询、监测和分娩计划,同时明确考虑合并症负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Pregnancy in autoimmune disease is increasingly feasible but carries heterogeneous maternal and perinatal risks beyond hypertensive disorders. We aimed to quantify disease-specific risks of maternal, foetal and neonatal outcomes across autoimmune diseases in a nationwide cohort, explicitly distinguishing primary vs secondary APS. METHODS: We analysed pregnancy-related hospitalizations in Spain (SNHDD, 2016-2022). Exposures were SLE, primary Sjögren syndrome (SjS), MCTD, SSc, sarcoidosis, Behçet disease and APS (primary/secondary). Outcomes included preeclampsia (PE), preeclampsia with severe features (PESC), composite maternal morbidity (caesarean delivery, postpartum hemorrhage, thrombosis, stroke, ICU admission) and composite foetal/neonatal morbidity-mortality (foetal distress, foetal growth restriction, preterm delivery, abruptio placentae, stillbirth, neonatal death). RESULTS: In 1 973 249 Spanish pregnancy hospitalizations, 5727 involved autoimmune disease. Risks clustered by disease: SLE (PE OR 1.78; PESC 2.17; composite maternal 1.35; foetal/neonatal 1.16), primary APS (PE 1.50; PESC 1.88; maternal 1.66; foetal/neonatal 1.10), secondary APS (PE 2.61; PESC 3.47; maternal 1.94) and MCTD (PE 4.57; PESC 7.24) showed the strongest signals. SSc increased composite maternal (1.62) and foetal/neonatal (1.69) risk; SjS raised caesarean and selected foetal outcomes; Behçet disease mainly increased maternal thrombosis (9.31); and sarcoidosis showed no independent associations. CONCLUSION: Pregnancies affected by autoimmune disease exhibit distinct, disease-specific patterns of hypertensive, maternal and foetal/neonatal risk, with the most consistently elevated risks observed in SLE, APS (especially secondary) and MCTD. These comparative estimates may support risk-stratified, guideline-concordant care and inform counseling, surveillance and delivery planning, with explicit consideration of comorbidity burden.
引用
- Esteban-Sampedro J, Martín-Portugués M, Ruiz-Irastorza G, et al. Impact of systemic autoimmune diseases in maternal, fetal and neonatal outcomes in Spain. Rheumatology (Oxford). 2026. PMID: 42421209. doi:10.1093/rheumatology/keag358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。